$1.600
-0.058 (-3.61%)At close
MYO News
MYO Events
Myomo Expects Q3 2026 Revenue Growth of 14%-19%
"In the third quarter of 2026, we expect continued year-over-year revenue growth with modestly higher operating expenses on a sequential basis, as we expand our MyoConnect program. We expect third quarter 2026 revenue to be in the range of $11.5 million to $12.0 million, up 14% to 19% year-over-year," said Paul Gudonis, Chairman and Chief Executive Officer of Myomo
Myomo Raises Full Year Revenue Guidance to $45M-$47M
"We are raising our full year revenue guidance to $45 million to $47 million. We reiterate our full year operating leverage expectation, and we expect cash burn to be less than $2 million during the second half of the year," said Paul Gudonis, Chairman and Chief Executive Officer of Myomo
Myomo Q2 Revenue Reaches $11.7M, Exceeds Expectations
Reports Q2 revenue $11.7M, consensus $10.35M. "I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, with 53% of second quarter revenues generated from referral network sources through our MyoConnect program and other sales channels. In addition, we generated operating leverage as we grew revenue 21% while holding operating expenses roughly flat," said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. "We believe our growing clinical referral network and the increased market awareness of our wearable robotics platform will lead to greater adoption by rehab clinicians and the hundreds of thousands of potential MyoPro candidates they treat. We anticipate continued progress on these initiatives and as a result are raising the revenue guidance to approximately 10-15% growth over the prior year."
Myomo Q1 Revenue $10.1M Exceeds Expectations
Reports Q1 revenue $10.1M, consensus $9.2M. "Earlier this year we established four success pillars for 2026, including growing revenue from recurring patient sources, increasing market access, demonstrating operating leverage and investing in innovation. With strong progress against each, first quarter revenue and operating results were above our targets. We are effectively shifting our business toward recurring patient sources, which represented 49% of revenue in the quarter, up from 25% a year ago. Our MyoConnect program is ramping up nicely and enhancing the clinical quality of prospective patients as well. This resulted in 11% of pipeline adds and 16% of orders generated by direct billing referrals in the quarter, with the added benefit of a sequential decline in cost per pipeline add," said Paul Gudonis, Myomo's Chairman and Chief Executive Officer.
Company Expects Q2 2026 Revenue of $10.3M to $10.8M
"With a strong backlog entering the second quarter, we expect to grow revenue sequentially with modestly higher operating expenses from increased advertising spend as changes made in our marketing program continue to gain traction," added Mr. Gudonis. "We expect second quarter 2026 revenue to be in the range of $10.3 million to $10.8 million. We reaffirm our guidance for full year revenue to be in the range of $43 million to $46 million and our prior full-year operating leverage expectation."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.